Skip to content

Efficacy of Diacerein on Ocular Surface Disease in Degenerative Arthritis Patients

Efficacy of Diacerein on Ocular Surface Disease in Degenerative Arthritis Patients

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04351100
Enrollment
34
Registered
2020-04-17
Start date
2019-10-01
Completion date
2020-07-31
Last updated
2021-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ocular Surface Disease, Osteoarthritis, Diacerein

Keywords

Dry Eye Syndromes, Osteoarthritis, Ocular surface inflammation, Interleukin-1, Interleukin-1 receptor antagonist

Brief summary

Dry eyes is multi-factorial disease which inflammation play etiological role. Diacerein is drug which has anti-inflammatory effect by antagonist Interleukin-1, decrease Interleukin-1 receptor, increase Interleukin-1 Receptor antagonist. This observational study enrolled participants who going to take diacerein for osteoarthritis, measure corneal staining score, Ocular surface disease index score, Tear Osmolarity, Tear break up time, Schirmer 1 test, Interleukin-1 Receptor antagonist, Interleukin-1 alpha, Interleukin-1 beta level in tear at the time of enrollment and after 2 months.

Interventions

Diacerein prescribing by orthopedist. Dry eye sign and symptom was asses before start diacerein and after 2 months.

Sponsors

Chulalongkorn University
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Osteoarthritis with 2. Ocular surface index score ≥ 13 with 3. Corneal staining score ≥ 3

Exclusion criteria

1. Allergic to diacerein 2. Use Cyclosporin within 30 days 3. Eyelid problem 4. Change artificial tear while in the study 5. Pregnancy or breast feeding

Design outcomes

Primary

MeasureTime frameDescription
Corneal staining score change from baseline at 2 monthsAt the time of enrollment and 2 monthsStain Cornea with Fluorescine, count and score staining at the cornea according to National eye institute : score 0-15 (0=no staining)

Secondary

MeasureTime frameDescription
Ocular surface disease index scoreAt the time of enrollment and 2 monthsOcular Surface Disease Index : 0-100 (0=no any symptom)
Tear OsmolarityAt the time of enrollment and 2 monthsUse Tearlab to measure tear osmolarity
Tear break up timeAt the time of enrollment and 2 monthsStain Cornea with Fluorescine, wait until tear film break, record time that tear break
Schirmer 1 testAt the time of enrollment and 2 monthsplace Schirmer strip at the fornix without anesthesia, wait for 5 min, record tear distance
Interleukin-1 receptor antagonist, Interleukin-1 alpha, Interleukin-1 beta level in tearAt the time of enrollment and 2 monthsExtract tear from Schirmer strip and use Bioplex for cytokine measurement of Interleukin-1 receptor antagonist(picogram/ml), Interleukin-1 alpha(picogram/ml), Interleukin-1 beta(picogram/ml)

Countries

Thailand

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026